We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

New Molecular Test Detects 14 High-Risk, Cancer-Causing HPV Genotypes

By LabMedica International staff writers
Posted on 06 Nov 2023
Print article
Image: The FDA has approved the Alinity m high risk (HR) HPV assay to be run on Alinity m (Photo courtesy of Abbott)
Image: The FDA has approved the Alinity m high risk (HR) HPV assay to be run on Alinity m (Photo courtesy of Abbott)

HPV (human papillomavirus) infections are exceedingly widespread, with most individuals who are sexually active encountering this virus during their lifetime. There's a vast array of HPV strains, each characterized by its own genetic makeup. Certain types of HPV are known to lead to cancers, such as cervical cancer in women. While Pap tests were traditionally the standard method for cervical cancer screening, current professional recommendations favor HPV testing as the initial step for screening, which is recognized as a more effective approach. Despite this, some of the HPV tests currently in use lack approval for primary screening and offer limited insights into the specific HPV genotypes involved. Now, a new HPV test uses molecular technology to provide genotype determination on the 14 high-risk HPV types that are most likely to cause cancer.

The Alinity m HR HPV assay from Abbott (Abbott Park, IL, USA) is a new molecular HPV screening solution that provides a powerful cancer screening tool for detecting high-risk HPV infections. The U.S. Food and Drug Administration (FDA) has approved the Alinity m high risk (HR) HPV assay as a test for HPV detection and for use in routine cervical cancer screening in line with professional medical guidelines. For those who choose to employ both tests, this assay can be used in conjunction with a Pap test, a dual approach known as co-testing. What sets the Alinity m HR HPV assay apart is its ability to categorize infections into five risk levels across the 14 high-risk HPV genotypes. This provides clinicians with crucial information, not only confirming the presence of an HPV infection but also indicating whether it's linked to a genotype with a higher risk of developing cancer. The Alinity m HR HPV assay will be available for use with Abbott's Alinity m system, a cutting-edge molecular PCR instrument that offers quick and high-volume testing capabilities.

"HPV testing is a powerful tool for detecting HPV infections that can lead to certain cancers, including cervical cancer and illustrates the power of molecular diagnostics in infectious disease," said Keith Cienkus, vice president of Abbott's molecular business. "The Alinity m HR HPV assay was carefully designed to support patient care and streamline HPV testing."

Related Links:
Abbott

Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Parainfluenza Virus Test
PARAINFLUENZA ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: Microscope image showing human colorectal cancer tumor with Fusobacterium nucleatum stained in a red-purple color (Photo courtesy of Fred Hutch Cancer Center)

Mouth Bacteria Test Could Predict Colon Cancer Progression

Colon cancer, a relatively common but challenging disease to diagnose, requires confirmation through a colonoscopy or surgery. Recently, there has been a worrying increase in colon cancer rates among younger... Read more

Pathology

view channel
Image: A new study has identified patterns that predict ovarian cancer relapse (Photo courtesy of Cedars-Sinai)

Spatial Tissue Analysis Identifies Patterns Associated With Ovarian Cancer Relapse

High-grade serous ovarian carcinoma is the most lethal type of ovarian cancer, and it poses significant detection challenges. Typically, patients initially respond to surgery and chemotherapy, but the... Read more